AstraZeneca won’t submit lung drug for COPD after 2nd study miss
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the…
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the…
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory,…
GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with…